Related references
Note: Only part of the references are listed.Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Iacopo Olivotto et al.
LANCET (2020)
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Steve R. Ommen et al.
CIRCULATION (2020)
The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporarymanagement of adult patients with cardiomyopathies
Philippe Charron et al.
EUROPEAN HEART JOURNAL (2018)
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Carolyn Y. Ho et al.
CIRCULATION (2018)
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Bernard J. Gersh et al.
CIRCULATION (2011)
Share Paper
